Tumor necrosis factor-alpha regulates mRNA for urokinase-type plasminogen activator and type-1 plasminogen activator inhibitor in human neoplastic cell lines - PubMed (original) (raw)
Tumor necrosis factor-alpha regulates mRNA for urokinase-type plasminogen activator and type-1 plasminogen activator inhibitor in human neoplastic cell lines
B Georg et al. Mol Cell Endocrinol. 1989 Jan.
Abstract
Tumor necrosis factor-alpha (TNF-alpha) was found to induce type-1 plasminogen activator inhibitor (PAI-1) antigen in the human fibrosarcoma cell line HT-1080, and PAI-1 and urokinase-type plasminogen activator (u-PA) antigens in the human carcinoma cell line T-CAR1; tissue-type plasminogen activator (t-PA) antigen was not affected or slightly decreased. The effects in HT-1080 and T-CAR1 cells were preceded by increases in the cellular levels of the corresponding mRNAs. Cycloheximide caused an increase of PAI-1 mRNA in T-CAR1 cells, but not in HT-1080 cells; during this increase the relative abundance of the two PAI-1 mRNA species, of 2.3 kb and 3.4 kb, respectively, changed strongly in favor of the longer transcript. We conclude that TNF-alpha may affect proteolytic activity in the microenvironment of cells in malignant tumors by affecting gene expression of u-PA and PAI-1.
Similar articles
- Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells.
van Hinsbergh VW, van den Berg EA, Fiers W, Dooijewaard G. van Hinsbergh VW, et al. Blood. 1990 May 15;75(10):1991-8. Blood. 1990. PMID: 2140060 - Glucocorticoid-modulated gene expression of tissue- and urinary-type plasminogen activator and plasminogen activator inhibitor 1 and 2.
Medcalf RL, Van den Berg E, Schleuning WD. Medcalf RL, et al. J Cell Biol. 1988 Mar;106(3):971-8. doi: 10.1083/jcb.106.3.971. J Cell Biol. 1988. PMID: 3126194 Free PMC article. - Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines.
Quax PH, van Leeuwen RT, Verspaget HW, Verheijen JH. Quax PH, et al. Cancer Res. 1990 Mar 1;50(5):1488-94. Cancer Res. 1990. PMID: 2105839 - Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin.
Seiffert D, Mimuro J, Schleef RR, Loskutoff DJ. Seiffert D, et al. Cell Differ Dev. 1990 Dec 2;32(3):287-92. doi: 10.1016/0922-3371(90)90041-t. Cell Differ Dev. 1990. PMID: 1711915 Review. - Plasminogen activation at the cell surface-matrix interface.
Vaheri A, Stephens RW, Salonen EM, Pöllänen J, Tapiovaara H. Vaheri A, et al. Cell Differ Dev. 1990 Dec 2;32(3):255-62. doi: 10.1016/0922-3371(90)90038-x. Cell Differ Dev. 1990. PMID: 2151565 Review. No abstract available.
Cited by
- Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.
Holland WL, Summers SA. Holland WL, et al. Endocr Rev. 2008 Jun;29(4):381-402. doi: 10.1210/er.2007-0025. Epub 2008 May 1. Endocr Rev. 2008. PMID: 18451260 Free PMC article. Review. - Modulation of the plasminogen activation system by inflammatory cytokines in human colon carcinoma cells.
Trân-Thang C, Kruithof E, Lahm H, Schuster WA, Tada M, Sordat B. Trân-Thang C, et al. Br J Cancer. 1996 Sep;74(6):846-52. doi: 10.1038/bjc.1996.447. Br J Cancer. 1996. PMID: 8826848 Free PMC article. - Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma.
Kristensen P, Pyke C, Lund LR, Andreasen PA, Danø K. Kristensen P, et al. Histochemistry. 1990;93(6):559-66. doi: 10.1007/BF00272198. Histochemistry. 1990. PMID: 2109745
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous